« In this issue of Blood, Rao et al reveal important insights into how hematopoietic stem cell (HSC) subpopulations contribute to myeloproliferative neoplasm (MPN) pathogenesis, and how these populations are perturbed in the setting of pegylated-interferon (pegIFN) therapy.1
The advent of pegylated forms of interferon (IFN) has provided renewed interest for use of this agent in the clinical setting. Recent studies demonstrate response rates on par with those of traditional cytoreductive therapy,2,3 and lower rates of discontinuation have been observed as a result of an improved toxicity profile in comparison with their nonpegylated counterparts. Importantly, unlike other currently available MPN therapies (including JAK inhibitors),4 IFN remains the only treatment in MPNs shown to reduce mutant clonal fraction and, in a minority of patients, induce molecular remissions,5 suggesting that pegIFN can selectively impair clonal outgrowth at the level of the mutant MPN stem cell. »